SYHA1815
SYHA1815 is an orally active RET inhibitor (IC50=0.9 nmol/L) with antitumor activity. SYHA1815 is more selective for RET than KDR (IC50=15.9 nmol/L) . SYHA1815 arrests the G1 cell cycle and inhibits RET-driven cell proliferation by downregulating c-Myc[1].
Product Specifications
CAS Number
2760195-67-1
UNSPSC
12352005
Target
C-Myc; RET; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/syha1815.html
Smiles
CN(CC1)CCN1CC2=C(C(F)(F)F)C=C(NC(C3=CC(F)=CC(C#CC4=CC=CN=C4N)=C3)=O)C=C2.Cl
Molecular Formula
C27H26ClF4N5O
Molecular Weight
547.97
References & Citations
[1]Yuchen Jiang, et al. "The novel RET inhibitor SYHA1815 inhibits RET-driven cancers and overcomes gatekeeper mutations by inducing G1 cell-cycle arrest through c-myc downregulation." Molecular Cancer Therapeutics 20.11 (2021) : 2198-2206.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471497-500 1x 500 µL
CD20 / MS4A1 (B-Cell Marker) (IGEL/1497R), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC043249-100 1x 100 µL
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/3249), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details